Aprea Therapeutics (APRE) Assets Average (2019 - 2026)
Aprea Therapeutics (APRE) posted quarterly Assets Average of $31.8 million for Q1 2026, up 43.76% year-over-year from $22.1 million in Q1 2025, and up 110.04% quarter-over-quarter from $15.1 million in Q4 2025.
Aprea Therapeutics (APRE) Assets Average (2019 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Assets Average for 8 consecutive years, with $31.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 43.76% year-over-year to $31.8 million; the TTM figure through Mar 2026 stood at $31.8 million (up 43.76% YoY), while the FY2025 annual figure was $20.0 million, down 14.4% from the prior year.
- Assets Average improved to $31.8 million in Q1 2026 per APRE's latest filing, from $15.1 million in the prior quarter.
- Across five years, Assets Average topped out at $53.6 million in Q1 2022 and bottomed at $15.1 million in Q4 2025.
- Historically, Assets Average has averaged $29.3 million across 5 years, with a median of $28.4 million in 2024.
- Annual changes were most pronounced in 2022 — Assets Average sank 46.54% — and 2026, when it soared 43.76%.
- Aprea Therapeutics' Assets Average stood at $31.9 million in 2022, then retreated by 24.09% to $24.2 million in 2023, then climbed by 5.07% to $25.4 million in 2024, then plunged by 40.53% to $15.1 million in 2025, then surged by 110.04% to $31.8 million in 2026.
- Business Quant data shows APRE's Assets Average at $31.8 million in Q1 2026, $15.1 million in Q4 2025, and $15.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 19.82 Bn |
| 10 | Aprea Therapeutics | 34.85 Mn | 34.85 Mn | - | 44.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.95 Mn |
| Mar 31, 2026 | 31.77 Mn |
| Dec 31, 2025 | 15.13 Mn |
| Sep 30, 2025 | 15.82 Mn |
| Jun 30, 2025 | 18.77 Mn |
| Mar 31, 2025 | 22.10 Mn |
| Dec 31, 2024 | 25.44 Mn |
| Sep 30, 2024 | 28.43 Mn |
| Jun 30, 2024 | 31.58 Mn |
| Mar 31, 2024 | 27.93 Mn |
| Dec 31, 2023 | 24.21 Mn |
| Sep 30, 2023 | 27.22 Mn |
| Jun 30, 2023 | 30.35 Mn |
| Mar 31, 2023 | 31.09 Mn |
| Dec 31, 2022 | 31.89 Mn |
| Sep 30, 2022 | 37.15 Mn |
| Jun 30, 2022 | 45.51 Mn |
| Mar 31, 2022 | 53.58 Mn |
| Dec 31, 2021 | 59.65 Mn |
| Sep 30, 2021 | 67.02 Mn |